EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Sacubitril/Valsartan Reduces Incident Anaemia and Iron Therapy Utilization in Heart Failure: The PARAGON-HF Trial

Henri Lu iD, Brian L Claggett, Milton Packer, Marc A Pfeffer, Carolyn S P Lam, Michael R Zile, Akshay S Desai, Pardeep Jhund, Martin Lefkowitz, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3414 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Henri Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Heart Failure, Aminobutyrates, Anemia, Tetrazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Renin–angiotensin system inhibitors (RASi) have been shown to lower haemoglobin levels, potentially related to reductions in erythropoietin levels and haematopoiesis. We examined whether sacubitril/valsartan might attenuate this effect of RASi alone on incident anaemia in patients with heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results PARAGON-HF was a global, multicentre randomized clinical trial of sacubitril/valsartan versus the RASi valsartan in patients with HF and left ventricular ejection fraction ≥45%. We evaluated haemoglobin trajectory and risks of incident anaemia and new iron therapy initiation during follow-up. Among 4795 participants, 1111 (23.2%) had anaemia at randomization and 5.6% were treated with iron at baseline. Over a median follow-up of 2.9 years, patients with anaemia were at significantly higher risk for total HF hospitalizations and cardiovascular death, compared with those without anaemia (21.6 vs. 11.5 per 100 patient-years; adjusted rate ratio 1.31; 95% confidence interval [CI] 1.12–1.54; p = 0.001). Sacubitril/valsartan slightly slowed the decline in haemoglobin levels by 0.1 g/dl (95% CI 0.0–0.2 g/dl; p = 0.005). Participants treated with sacubitril/valsartan were at significantly lower risk of developing anaemia (30.3% vs. 37.6%; hazard ratio [HR] 0.76; 95% CI 0.68–0.85; p < 0.001) and starting iron therapy (8.1% vs. 10.0%; HR 0.81; 95% CI 0.67–0.97; p = 0.026). Treatment effects of sacubitril/valsartan versus valsartan on total HF hospitalizations and cardiovascular death were consistent among patients across the haemoglobin spectrum (pinteraction = 0.60).

Conclusions

Among patients with HFmrEF/HFpEF, treatment with sacubitril/valsartan resulted in modestly smaller declines in haemoglobin, lower rates of incident anaemia, and fewer new initiations of iron therapy compared with RASi. Clinical Trial Registration: ClinicalTrials.gov ID NCT01920711.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAminobutyratesAnemiaTetrazolesIronHumansBiphenyl CompoundsMaleFemaleValsartanDrug CombinationsAgedAngiotensin Receptor AntagonistsStroke VolumeIncidenceMiddle AgedTreatment OutcomeHemoglobinsFollow-Up Studies

Stichwörter der Autor:innen

AnaemiaHeart failureSacubitril/valsartan

Substanzen

Biphenyl CompoundsAminobutyratesValsartansacubitril and valsartan sodium hydrate drug combinationDrug CombinationsAngiotensin Receptor AntagonistsTetrazolesIronHemoglobins

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
  • Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, TX, USA.
  • National Heart Centre Singapore, Singapore, Singapore.
  • Medical University of South Carolina, Charleston, SC, USA.
  • BHF Glasgow Cardiovascular Research Centre, Glasgow, UK.

ORCID-Profile: Henri Lu

Förderung

  • Novartis

Zitieren

APA

Lu, H., Claggett, B. L., Packer, M., Pfeffer, M. A., Lam, C. S. P., Zile, M. R., Desai, A. S., Jhund, P., Lefkowitz, M., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2025). Sacubitril/Valsartan Reduces Incident Anaemia and Iron Therapy Utilization in Heart Failure: The PARAGON-HF Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3414

Vancouver

Lu H, Claggett BL, Packer M, Pfeffer MA, Lam CSP, Zile MR, et al. Sacubitril/Valsartan Reduces Incident Anaemia and Iron Therapy Utilization in Heart Failure: The PARAGON-HF Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3414

BibTeX
@article{Lu2025,
  author = {Lu, Henri and Claggett, Brian L and Packer, Milton and Pfeffer, Marc A and Lam, Carolyn S P and Zile, Michael R and Desai, Akshay S and Jhund, Pardeep and Lefkowitz, Martin and McMurray, John J V and Solomon, Scott D and Vaduganathan, Muthiah},
  title = {Sacubitril/Valsartan Reduces Incident Anaemia and Iron Therapy Utilization in Heart Failure: The PARAGON-HF Trial},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3414}
}
Kostenlos starten →